| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
5A2-SC8 targets the delivery of small RNAs (siRNA, miRNA) to tumor cells. It is an ionizable amino lipid used in lipid nanoparticles (LNPs) for RNA delivery. The ApoE protein corona adsorbs on the surface of 5A2-SC8 LNPs, binds to LDL-R on the surface of hepatocytes, and undergoes receptor-mediated endocytosis.
|
|---|---|
| ln Vitro |
In vitro, 5A2-SC8 is used as an ionizable amino lipid in LNPs for small RNA delivery. It shows high delivery potential. The ApoE protein corona adsorbs on the surface of 5A2-SC8 LNPs, binds to LDL-R on hepatocytes, and undergoes receptor-mediated endocytosis. It enables efficient delivery of siRNA and miRNA into tumor cells.
|
| ln Vivo |
In vivo, 5A2-SC8 (75 mg/kg; i.v.; single-dose) is well tolerated and does not affect survival in mice with chronic aggressive hepatocellular carcinoma. 5A2-SC8 (0.5 mg/kg; i.v.; single-dose) can pass the first barrier of Kupffer cells in the liver and be internalized into hepatocytes. It is used for efficient delivery of small RNAs such as siRNA and miRNA into tumor cells.
|
| Enzyme Assay |
There are no in vitro enzyme/receptor binding assays for 5A2-SC8 as it is a lipid for RNA delivery, not an enzyme inhibitor. Its function is assessed by its ability to deliver RNA into cells.
|
| Cell Assay |
In vitro cell-based assays for 5A2-SC8 involve formulating the lipid into LNPs with small RNAs and treating cells with the LNPs. RNA delivery efficiency is assessed by measuring the knockdown of target genes (for siRNA) or expression of reporter genes (for mRNA). Cell viability and toxicity are also evaluated.
|
| Animal Protocol |
In vivo animal studies for 5A2-SC8 involve administering 5A2-SC8 LNPs containing small RNAs to mice via intravenous injection. RNA delivery to the liver and tumor tissues is assessed. Therapeutic outcomes in cancer models are evaluated. Survival and toxicity are monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5A2-SC8 are not extensively detailed in the available literature. The compound is soluble in DMSO: 100 mg/mL (54.30 mM; Need ultrasonic). For storage, powder should be kept at -20°C, protect from light, stored under nitrogen; in solvent at -80°C for 6 months or -20°C for 1 month (protect from light, stored under nitrogen).
|
| Toxicity/Toxicokinetics |
No specific toxicity data for 5A2-SC8 are available in the provided literature. It shows low in vivo toxicity. 5A2-SC8 (75 mg/kg; i.v.; single-dose) is well tolerated in mice. The compound is for research use only.
|
| References | |
| Additional Infomation |
5A2-SC8 is an ionizable amino lipid for RNA delivery. It shows high delivery potential and low in vivo toxicity. It is used for efficient delivery of siRNA and miRNA into tumor cells. Its CAS number is 1857341-90-2.
|
| Molecular Formula |
C93H173N5O20S5
|
|---|---|
| Molecular Weight |
1841.72
|
| Exact Mass |
1840.127
|
| CAS # |
1857341-90-2
|
| PubChem CID |
129092701
|
| Appearance |
Colorless to light yellow ointment
|
| LogP |
20.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
30
|
| Rotatable Bond Count |
102
|
| Heavy Atom Count |
123
|
| Complexity |
2340
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCSCC(C)C(=O)OCCOC(=O)CCN(CCC(=O)OCCOC(=O)C(C)CSCCCCCCCC)CCNCCN(CCC(=O)OCCOC(=O)C(C)CSCCCCCCCC)CCNCCN(CCC(=O)OCCOC(=O)C(C)CSCCCCCCCC)CCC(=O)OCCOC(=O)C(C)CSCCCCCCCC
|
| InChi Key |
BYWPQQOQVPVCTC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C93H173N5O20S5/c1-11-16-21-26-31-36-69-119-74-79(6)89(104)114-64-59-109-84(99)41-50-96(51-42-85(100)110-60-65-115-90(105)80(7)75-120-70-37-32-27-22-17-12-2)55-46-94-48-57-98(54-45-88(103)113-63-68-118-93(108)83(10)78-123-73-40-35-30-25-20-15-5)58-49-95-47-56-97(52-43-86(101)111-61-66-116-91(106)81(8)76-121-71-38-33-28-23-18-13-3)53-44-87(102)112-62-67-117-92(107)82(9)77-122-72-39-34-29-24-19-14-4/h79-83,94-95H,11-78H2,1-10H3
|
| Chemical Name |
2-[3-[2-[2-[2-[2-[bis[3-[2-(2-methyl-3-octylsulfanylpropanoyl)oxyethoxy]-3-oxopropyl]amino]ethylamino]ethyl-[3-[2-(2-methyl-3-octylsulfanylpropanoyl)oxyethoxy]-3-oxopropyl]amino]ethylamino]ethyl-[3-[2-(2-methyl-3-octylsulfanylpropanoyl)oxyethoxy]-3-oxopropyl]amino]propanoyloxy]ethyl 2-methyl-3-octylsulfanylpropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~54.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5430 mL | 2.7149 mL | 5.4297 mL | |
| 5 mM | 0.1086 mL | 0.5430 mL | 1.0859 mL | |
| 10 mM | 0.0543 mL | 0.2715 mL | 0.5430 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
